A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

NCT01227889 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

251

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: GSK2118436
DRUG: Dacarbazine (DTIC)

Sponsor

GlaxoSmithKline